Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

Company Overview

Finch Therapeutics Group, Inc. is a biotechnology company focused on developing microbiome-based therapies for diseases associated with disruptions in the human gut microbiome. The company uses its Human-First Discovery platform, which combines clinical data, microbial analysis and biological research to identify therapeutic candidates derived from or designed to influence the microbiome.

Finch’s lead development program has been FIN-211, an orally administered microbiome therapy investigated for autism spectrum disorder, particularly in patients experiencing gastrointestinal symptoms. The company has also historically pursued microbiome-based candidates for inflammatory and gastrointestinal diseases, including programs targeting conditions such as Crohn’s disease and ulcerative colitis.

Founded in Cambridge, Massachusetts, Finch has conducted its research and clinical development activities primarily in the United States. Its programs and corporate strategy have changed over time as the company has restructured its pipeline, and information about the status of individual candidates may vary by reporting period. Finch’s work has centered on translating insights from human microbiome research into potential prescription therapies.

Key Stats

• Today's Range: $7.30 to $7.30
• 50-Day Range: $7.30 to $7.30
• 52-Week Range: $2.00 to $16.10
• Volume: N/A
• Average Volume: 5,025 shs
• Market Capitalization: $11.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/10/2021
• Today: 9/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:FNCH
• CIK: 1733257
• Web: www.finchtherapeutics.com
• Phone: 617-229-6499
• Fax: N/A
• Employees: 190
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($8.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.75 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -69.14%
• Return on Assets: -26.92%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.87
• Quick Ratio: 3.87

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $14.25 per share
• Price / Book: 0.51

Miscellaneous

• Outstanding Shares: 1,606,000
• Free Float: 885,000
• Market Cap: $11.72 million
• Optionable: No Data
• Beta: 1.18